Hypera Valuation

Is HM6A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HM6A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HM6A (€3.52) is trading below our estimate of fair value (€10.32)

Significantly Below Fair Value: HM6A is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for HM6A?

Other financial metrics that can be useful for relative valuation.

HM6A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA8.3x
PEG Ratio0.7x

Price to Earnings Ratio vs Peers

How does HM6A's PE Ratio compare to its peers?

The above table shows the PE ratio for HM6A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.9x
DMP Dermapharm Holding
20.2x20.0%€1.7b
PSG PharmaSGP Holding
16.3x14.6%€297.4m
2FJ0 Pierrel
29.9xn/a€92.8m
MRK Merck KGaA
25.1x10.6%€65.8b
HM6A Hypera
8x12.0%€14.0b

Price-To-Earnings vs Peers: HM6A is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (22.9x).


Price to Earnings Ratio vs Industry

How does HM6A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: HM6A is good value based on its Price-To-Earnings Ratio (8x) compared to the European Pharmaceuticals industry average (21.8x).


Price to Earnings Ratio vs Fair Ratio

What is HM6A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HM6A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8x
Fair PE Ratio16x

Price-To-Earnings vs Fair Ratio: HM6A is good value based on its Price-To-Earnings Ratio (8x) compared to the estimated Fair Price-To-Earnings Ratio (16x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies